Aug 2026· International Journal of Molecular Sciences· Vol 27· 0 citations· 68 references
Medicine
TL;DR
Integrative analysis of multi–omics data provided robust prognostic stratification in ovarian cancer while capturing the underlying molecular and biological features.
Abstract
Ovarian cancer exhibits clinical heterogeneity; reliable prognostic stratification remains challenging despite extensive biomarker research. We performed an integrative analysis of transcriptomic and proteomic data to identify prognostically distinct molecular clusters in ovarian cancer. Using The Cancer Genome Atlas dataset, RNA sequencing and reverse–phase protein array data from 146 overlapping samples were analyzed. Genes (n = 150) and proteins (n = 67) showing nominal associations with overall survival (p < 0.05) were integrated; k–means clustering identified two patient clusters with highly significant differences in survival (p = 8.59 × 10−15). The SAR2 and ACTN4 genes and their corresponding protein expression levels showed high correlations among the significant genes and proteins (correlation coefficients > 0.80). Gene set enrichment analysis revealed that genes regulated by the PAX2 and BCL6 transcription factors were significantly enriched. The identified clusters were validated across six independent public transcriptomic datasets comprising 617 patients; consistent survival separation was observed between the patient clusters (p < 0.05). Clustering based on immunohistochemistry–derived expression profiles of nine proteins in an independent patient cohort demonstrated a significant difference in survival (p = 0.04). Integrative analysis of multi–omics data provided robust prognostic stratification in ovarian cancer while capturing the underlying molecular and biological features.
MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.
Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al.· Cancer Genomics & Proteomics· 0 citations
This integrated transcriptomic and experimental validation study identifies FOXQ1 and MCM10 as key regulators in ovarian cancer, highlighting their potential as biomarkers for disease progression.
D. Suryandari, L. Yunaini, Khaerunissa Anbar Istiadi et al.· Eurasian Journal of Medicine...· 0 citations
It is suggested that IL1RAP and IRF2BP2 may be important in immune-related and candidated biomarker identification in breast cancer PDOs, and an integrated transcriptomic, enrichment and network-based analyses for a robust strategy for biomarker discovery are integrated.
S. Scippa, A. Balestrieri, M. Zanfardino et al.· Frontiers in Bioengineering...· 0 citations
This study defines a cross-population gene signature driving TSCC through ECM remodeling and immune modulation, and validation of STC2 as a prognostic marker highlights its potential for clinical risk stratification.
These results identify seven tissue-transcriptomic candidates with strong dataset-specific discriminative performance and provide a multidimensional biological framework warranting experimental validation and prospective clinical evaluation.
Zeynep Mutlu Coskun, Muhammet Coskun, Saime Sezer Sondaş· Current Issues in Molecular...· 0 citations
Findings support hsa-miR-200a as a potential breast cancer-associated miRNA biomarker candidate and highlight the utility of integrative transcriptomic and exploratory clinical serum approaches for future precision diagnostics.
Kwangmin Park, Eun You Kim, Eun Ju Lee et al.· Genes & Genomics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.